Intellia Therapeutics (NASDAQ:NTLA) Trading Down 6.6% – Should You Sell?

Intellia Therapeutics, Inc. (NASDAQ:NTLA)’s share price dropped 6.6% on Friday . The company traded as low as $14.96 and last traded at $14.8240. Approximately 1,047,110 shares changed hands during trading, a decline of 76% from the average daily volume of 4,438,837 shares. The stock had previously closed at $15.87.

Wall Street Analyst Weigh In

NTLA has been the subject of several research analyst reports. Chardan Capital restated a “buy” rating and set a $26.00 price objective on shares of Intellia Therapeutics in a research report on Friday, February 27th. Leerink Partners lifted their price target on Intellia Therapeutics from $27.00 to $29.00 and gave the company an “outperform” rating in a research note on Tuesday, March 3rd. Wells Fargo & Company upped their price objective on Intellia Therapeutics from $12.00 to $15.00 and gave the stock an “equal weight” rating in a research report on Tuesday, March 3rd. Wall Street Zen upgraded Intellia Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, March 7th. Finally, KeyCorp set a $25.00 price target on shares of Intellia Therapeutics in a research note on Wednesday, January 28th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, Intellia Therapeutics presently has an average rating of “Hold” and an average target price of $19.52.

Intellia Therapeutics Trading Down 4.6%

The company’s 50-day simple moving average is $13.53 and its 200-day simple moving average is $13.15. The stock has a market capitalization of $1.79 billion, a price-to-earnings ratio of -3.95 and a beta of 1.99.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings results on Thursday, February 26th. The company reported ($0.83) EPS for the quarter, topping analysts’ consensus estimates of ($0.99) by $0.16. The company had revenue of $23.02 million for the quarter, compared to analyst estimates of $12.17 million. Intellia Therapeutics had a negative net margin of 609.85% and a negative return on equity of 56.81%. Intellia Therapeutics’s revenue was up 78.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.27) earnings per share. On average, equities research analysts expect that Intellia Therapeutics, Inc. will post -3.53 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Intellia Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Pictet Asset Management Holding SA raised its position in shares of Intellia Therapeutics by 47.2% during the first quarter. Pictet Asset Management Holding SA now owns 16,933 shares of the company’s stock worth $217,000 after acquiring an additional 5,429 shares during the last quarter. Lewis Asset Management LLC boosted its holdings in Intellia Therapeutics by 38.5% in the first quarter. Lewis Asset Management LLC now owns 19,770 shares of the company’s stock valued at $253,000 after acquiring an additional 5,500 shares during the last quarter. SG Americas Securities LLC increased its position in Intellia Therapeutics by 22.6% during the 1st quarter. SG Americas Securities LLC now owns 89,688 shares of the company’s stock valued at $1,150,000 after purchasing an additional 16,545 shares during the period. Rockefeller Capital Management L.P. raised its holdings in Intellia Therapeutics by 1.7% during the 4th quarter. Rockefeller Capital Management L.P. now owns 140,218 shares of the company’s stock worth $1,261,000 after purchasing an additional 2,277 shares during the last quarter. Finally, Virtu Financial LLC bought a new position in Intellia Therapeutics during the 4th quarter worth approximately $245,000. Institutional investors and hedge funds own 88.77% of the company’s stock.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.